{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:22:16Z","timestamp":1787908936984,"version":"build-2784847793"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2022QH391"],"award-info":[{"award-number":["ZR2022QH391"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05630-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:13:25Z","timestamp":1783498405000},"page":"3831-3856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["METTL3\u2013YTHDF1\u2013driven m6A enhancement of MYC signaling orchestrates DNA repair and metabolic reprogramming to promote chemoresistance in colorectal cancer"],"prefix":"10.1007","volume":"481","author":[{"given":"Kai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"5630_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081530","volume":"16","author":"G Roshandel","year":"2024","unstructured":"Roshandel G, Ghasemi-Kebria F, Malekzadeh R (2024) Colorectal cancer: epidemiology, risk factors, and prevention. Cancers 16:1530","journal-title":"Cancers"},{"key":"5630_CR2","doi-asserted-by":"crossref","unstructured":"Zhang T, Guo Y, Qiu B et al (2025) Global, regional, and national trends in colorectal cancer burden from 1990 to 2021 and projections to 2040. Front. Oncol. 14","DOI":"10.3389\/fonc.2024.1466159"},{"key":"5630_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.20517\/cdr.2022.136","volume":"6","author":"WH Gmeiner","year":"2023","unstructured":"Gmeiner WH, Okechukwu CC (2023) Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist 6:257\u2013272","journal-title":"Cancer Drug Resist"},{"key":"5630_CR4","doi-asserted-by":"crossref","unstructured":"Oh JM, Kim S, Tsung C et al (2025) Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type. Front Immunol 16","DOI":"10.3389\/fimmu.2025.1571731"},{"key":"5630_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1340401","author":"N Albadari","year":"2024","unstructured":"Albadari N, Xie Y, Li W (2024) Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF\/c-MET signaling. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1340401","journal-title":"Front Pharmacol"},{"key":"5630_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137470","volume":"25","author":"M Barathan","year":"2024","unstructured":"Barathan M, Zulpa AK, Ng SL et al (2024) Innovative strategies to combat 5-fluorouracil resistance in colorectal cancer: the role of phytochemicals and extracellular vesicles. Int J Mol Sci 25:7470","journal-title":"Int J Mol Sci"},{"key":"5630_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092605","volume":"12","author":"JJG Marin","year":"2020","unstructured":"Marin JJG, Macias RIR, Monte MJ et al (2020) Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment. Cancers 12:2605","journal-title":"Cancers"},{"key":"5630_CR8","doi-asserted-by":"crossref","unstructured":"Lin J-F, Liu Z-X, Chen D-L et al (2025) Nucleus-translocated GCLM promotes chemoresistance in colorectal cancer through a moonlighting function. Nat Commun 16","DOI":"10.1038\/s41467-024-55568-1"},{"key":"5630_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02670-y","author":"X Qiu","year":"2025","unstructured":"Qiu X, Wang A, Wang J et al (2025) Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions. Cell Death Discov. https:\/\/doi.org\/10.1038\/s41420-025-02670-y","journal-title":"Cell Death Discov"},{"key":"5630_CR10","doi-asserted-by":"crossref","unstructured":"Nesic K, Parker P, Swisher EM, Krais JJ (2025) DNA repair and the contribution to chemotherapy resistance. Genome Med 17","DOI":"10.1186\/s13073-025-01488-8"},{"key":"5630_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01857-7","author":"B Wilczy\u0144ski","year":"2024","unstructured":"Wilczy\u0144ski B, D\u0105browska A, Kulbacka J, Baczy\u0144ska D (2024) Chemoresistance and the tumor microenvironment: the critical role of cell\u2013cell communication. Cell Commun Signal. https:\/\/doi.org\/10.1186\/s12964-024-01857-7","journal-title":"Cell Commun Signal"},{"key":"5630_CR12","doi-asserted-by":"crossref","unstructured":"Wang H, Tang R, Jiang L, Jia Y (2024) The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies. Front Pharmacol 15","DOI":"10.3389\/fphar.2024.1494802"},{"key":"5630_CR13","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.ajpath.2025.06.013","volume":"195","author":"Y Xu","year":"2025","unstructured":"Xu Y, Qin C, Zhang M et al (2025) NSUN5 Mediates Resistance to Doxorubicin via Up-regulation of DNA Damage Repair Proteins BRCA2 and BRIP1 in Colorectal Cancer. Am J Pathol 195:1921\u20131935. https:\/\/doi.org\/10.1016\/j.ajpath.2025.06.013","journal-title":"Am J Pathol"},{"key":"5630_CR14","doi-asserted-by":"crossref","unstructured":"Dong J, Yuan L, Hu C, et al (2023) Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review. Pharmacology & Therapeutics 249:108488","DOI":"10.1016\/j.pharmthera.2023.108488"},{"key":"5630_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051245","volume":"13","author":"Y-C Li","year":"2025","unstructured":"Li Y-C, Xiong Y-M, Long Z-P et al (2025) ML210 antagonizes ABCB1- not ABCG2-mediated multidrug resistance in colorectal cancer. Biomedicines 13:1245. https:\/\/doi.org\/10.3390\/biomedicines13051245","journal-title":"Biomedicines"},{"key":"5630_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102156","volume":"50","author":"R Qin","year":"2024","unstructured":"Qin R, Fan X, Huang Y et al (2024) Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance. Transl Oncol 50:102156","journal-title":"Transl Oncol"},{"key":"5630_CR17","doi-asserted-by":"crossref","unstructured":"Chen X, Ma Z, Yi Z et al (2024) The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Discov. 10","DOI":"10.1038\/s41420-024-01865-z"},{"key":"5630_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036394","volume":"102","author":"Y Lin","year":"2023","unstructured":"Lin Y, Shi H, Wu L et al (2023) Research progress of N6-methyladenosine in colorectal cancer: a review. Medicine (Baltimore) 102:e36394","journal-title":"Medicine (Baltimore)"},{"key":"5630_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J (2020) m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell 37:270\u2013288","journal-title":"Cancer Cell"},{"key":"5630_CR20","doi-asserted-by":"crossref","unstructured":"Gao Z, Zha X, Li M et al (2024) Insights into the m6A demethylases FTO and ALKBH5 : structural, biological function, and inhibitor development. Cell Biosci 14","DOI":"10.1186\/s13578-024-01286-6"},{"key":"5630_CR21","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.21037\/tcr-23-2401","volume":"13","author":"Z Dou","year":"2024","unstructured":"Dou Z, Ma X-T, Piao M-N et al (2024) Overview of the interplay between m6A methylation modification and non-coding RNA and their impact on tumor cells. Transl Cancer Res 13:3106\u20133125","journal-title":"Transl Cancer Res"},{"key":"5630_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1464042","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Peng L, Yang X et al (2024) N6-methyladenosine RNA methylation, a new hallmark of metabolic reprogramming in the immune microenvironment. Front Immunol 15:1464042. https:\/\/doi.org\/10.3389\/fimmu.2024.1464042","journal-title":"Front Immunol"},{"key":"5630_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/molecules29010140","volume":"29","author":"H Rong","year":"2023","unstructured":"Rong H, Wang D, Wang Y et al (2023) YTHDF1 in Tumor Cell Metabolism: An Updated Review. Molecules 29:140","journal-title":"Molecules"},{"key":"5630_CR24","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s12013-024-01610-4","volume":"83","author":"L Han","year":"2025","unstructured":"Han L, Wang R, He M et al (2025) METTL3\/YTDHF1 Stabilizes CSRP1 mRNA to Regulate Glycolysis and Promote Acute Myeloid Leukemia Progression. Cell Biochem Biophys 83:1993\u20132007. https:\/\/doi.org\/10.1007\/s12013-024-01610-4","journal-title":"Cell Biochem Biophys"},{"key":"5630_CR25","doi-asserted-by":"crossref","unstructured":"Tang X, Guo M, Zhang Y et al (2024) Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects. J Exp Clin Cancer Res 43","DOI":"10.1186\/s13046-024-03136-2"},{"key":"5630_CR26","doi-asserted-by":"crossref","unstructured":"Shao C, Han Y, Huang Y et al (2023) Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review). Int J Oncol 64","DOI":"10.3892\/ijo.2023.5605"},{"key":"5630_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01782-2","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Yu B, Tao D et al (2023) The role of m6A methylation in therapy resistance in cancer. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-023-01782-2","journal-title":"Mol Cancer"},{"key":"5630_CR28","doi-asserted-by":"crossref","unstructured":"Tang L, Tian H, Min Q et al (2024) Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance. Cell Commun Signal 22","DOI":"10.1186\/s12964-024-01854-w"},{"key":"5630_CR29","doi-asserted-by":"crossref","unstructured":"Jha RK, Kouzine F, Levens D (2023) MYC function and regulation in physiological perspective. Front Cell Dev Biol 11","DOI":"10.3389\/fcell.2023.1268275"},{"key":"5630_CR30","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.gendis.2024.101435","volume":"12","author":"Y Duan","year":"2024","unstructured":"Duan Y, Liu Z, Wang Q et al (2024) Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology. Genes Dis 12:101435. https:\/\/doi.org\/10.1016\/j.gendis.2024.101435","journal-title":"Genes Dis"},{"key":"5630_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/pathophysiology30030031","volume":"30","author":"ZO Doha","year":"2023","unstructured":"Doha ZO, Sears RC (2023) Unraveling MYC\u2019s Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance. Pathophysiology 30:400\u2013419","journal-title":"Pathophysiology"},{"key":"5630_CR32","doi-asserted-by":"crossref","unstructured":"Zhou M, He J, Li Y et al (2023) N6-methyladenosine modification of REG1\u03b1 facilitates colorectal cancer progression via \u03b2-catenin\/MYC\/LDHA axis mediated glycolytic reprogramming. Cell Death Dis 14","DOI":"10.1038\/s41419-023-06067-6"},{"key":"5630_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41420-025-02623-5","volume":"11","author":"B Pang","year":"2025","unstructured":"Pang B, Wu H (2025) Metabolic reprogramming in colorectal cancer: a review of aerobic glycolysis and its therapeutic implications for targeted treatment strategies. Cell Death Discov 11:321. https:\/\/doi.org\/10.1038\/s41420-025-02623-5","journal-title":"Cell Death Discov"},{"key":"5630_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132255","volume":"17","author":"JR Evans","year":"2025","unstructured":"Evans JR, Wang J, Reed CN et al (2025) MYC regulates a DNA repair gene expression program in small cell carcinoma of the ovary, hypercalcemic type. Cancers (Basel) 17:2255. https:\/\/doi.org\/10.3390\/cancers17132255","journal-title":"Cancers (Basel)"},{"key":"5630_CR35","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.62347\/RTVX8866","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ye M, Luan X et al (2025) Exploiting replication stress for synthetic lethality in MYC-driven cancers. Am J Cancer Res 15:1461\u20131479. https:\/\/doi.org\/10.62347\/RTVX8866","journal-title":"Am J Cancer Res"},{"issue":"1","key":"5630_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12935-025-03758-2","volume":"25","author":"A Babajnai","year":"2025","unstructured":"Babajnai A, Rahmani S, Asadi MJ et al (2025) Molecular and phenotypic characterization of 5-FU resistant colorectal cancer cells: toward enrichment of cancer stem cells. Cancer Cell Int 25:154. https:\/\/doi.org\/10.1186\/s12935-025-03758-2","journal-title":"Cancer Cell Int"},{"key":"5630_CR37","doi-asserted-by":"crossref","unstructured":"Li F, Lin Y, Li R et al (2023) Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches. Front Pharmacol 14","DOI":"10.3389\/fphar.2023.1165666"},{"key":"5630_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/cells13030245","volume":"13","author":"PW Underwood","year":"2024","unstructured":"Underwood PW, Ruff SM, Pawlik TM (2024) Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. Cells 13:245","journal-title":"Cells"},{"key":"5630_CR39","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/biomedicines13030642","volume":"13","author":"SH Shaham","year":"2025","unstructured":"Shaham SH, Vij P, Tripathi MK (2025) Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions. Biomedicines 13:642. https:\/\/doi.org\/10.3390\/biomedicines13030642","journal-title":"Biomedicines"},{"key":"5630_CR40","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/ijms25020874","volume":"25","author":"P Ajithkumar","year":"2024","unstructured":"Ajithkumar P, Vasantharajan SS, Pattison S et al (2024) Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis. IJMS 25:874","journal-title":"IJMS"},{"key":"5630_CR41","doi-asserted-by":"crossref","unstructured":"Gao J, Shi W, Wang J et al (2024) Research progress and applications of epigenetic biomarkers in cancer. Front Pharmacol 15","DOI":"10.3389\/fphar.2024.1308309"},{"key":"5630_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01740-9","author":"T Dang","year":"2024","unstructured":"Dang T, Guan X, Cui L et al (2024) Epigenetics and immunotherapy in colorectal cancer: progress and promise. Clin Epigenetics. https:\/\/doi.org\/10.1186\/s13148-024-01740-9","journal-title":"Clin Epigenetics"},{"key":"5630_CR43","doi-asserted-by":"publisher","first-page":"58194","DOI":"10.1021\/acsomega.5c03607","volume":"10","author":"M Trofimov","year":"2025","unstructured":"Trofimov M, Bulatov I, Donskaia I et al (2025) Three-Dimensional Tumor Spheroids of Pancreatic and Colorectal Cancer Cell Lines for High-Throughput Screening of Drug Candidates. ACS Omega 10:58194\u201358204. https:\/\/doi.org\/10.1021\/acsomega.5c03607","journal-title":"ACS Omega"},{"key":"5630_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160606","author":"J Jin","year":"2022","unstructured":"Jin J, Wu Y, Zhao Z et al (2022) Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.160606","journal-title":"JCI Insight"},{"key":"5630_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.lungcan.2018.10.016","volume":"126","author":"TWH Meijer","year":"2018","unstructured":"Meijer TWH, Peeters WJM, Dubois LJ et al (2018) Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer. Lung Cancer 126:32\u201340","journal-title":"Lung Cancer"},{"key":"5630_CR46","doi-asserted-by":"crossref","unstructured":"Duan R, Zhai Y, Wang Q et al (2024) LINC01764 promotes colorectal cancer cells proliferation, metastasis, and 5-fluorouracil resistance by regulating glucose and glutamine metabolism via promoting c\u2010MYC translation. MedComm 5","DOI":"10.1002\/mco2.70003"},{"key":"5630_CR47","doi-asserted-by":"crossref","unstructured":"Liu C, Li C, Liu Y (2023) The role of metabolic reprogramming in pancreatic cancer chemoresistance. Front Pharmacol 13","DOI":"10.3389\/fphar.2022.1108776"},{"key":"5630_CR48","doi-asserted-by":"crossref","unstructured":"Xia Y, Zhang L, Ocansey DKW et al (2023) Role of glycolysis in inflammatory bowel disease and its associated colorectal cancer. Front Endocrinol 14","DOI":"10.3389\/fendo.2023.1242991"},{"key":"5630_CR49","doi-asserted-by":"crossref","unstructured":"Jin Q, Qu H, Quan C (2023) New insights into the regulation of METTL3 and its role in tumors. Cell Commun Signal 21","DOI":"10.1186\/s12964-023-01360-5"},{"key":"5630_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae009","author":"M Esteva-Socias","year":"2024","unstructured":"Esteva-Socias M, Aguilo F (2024) METTL3 as a master regulator of translation in cancer: mechanisms and implications. NAR Cancer. https:\/\/doi.org\/10.1093\/narcan\/zcae009","journal-title":"NAR Cancer"},{"key":"5630_CR51","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang X, Zhao BS, Roundtree IA et al (2015) N6-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell 161:1388\u20131399","journal-title":"Cell"},{"key":"5630_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217186","volume":"601","author":"Y Han","year":"2024","unstructured":"Han Y, Pu Y, Liu X et al (2024) YTHDF1 regulates GID8-mediated glutamine metabolism to promote colorectal cancer progression in m6A-dependent manner. Cancer Lett 601:217186","journal-title":"Cancer Lett"},{"key":"5630_CR53","doi-asserted-by":"crossref","unstructured":"Zeng C, Huang W, Li Y, Weng H (2020) Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol 13","DOI":"10.1186\/s13045-020-00951-w"},{"key":"5630_CR54","doi-asserted-by":"crossref","unstructured":"Shi Y, Zheng C, Jin Y et al (2020) Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation. Front. Oncol. 10","DOI":"10.3389\/fonc.2020.01126"},{"key":"5630_CR55","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.cell.2020.05.012","volume":"181","author":"S Zaccara","year":"2020","unstructured":"Zaccara S, Jaffrey SR (2020) A Unified Model for the Function of YTHDF Proteins in Regulating m6A-Modified mRNA. Cell 181:1582\u20131595e18","journal-title":"Cell"},{"key":"5630_CR56","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.omtn.2021.10.023","volume":"26","author":"Z Chen","year":"2021","unstructured":"Chen Z, Zhong X, Xia M, Zhong J (2021) The roles and mechanisms of the m6A reader protein YTHDF1 in tumor biology and human diseases. Mol Therapy - Nucleic Acids 26:1270\u20131279","journal-title":"Mol Therapy - Nucleic Acids"},{"key":"5630_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01841-8","author":"S-W Yue","year":"2023","unstructured":"Yue S-W, Liu H-L, Su H-F et al (2023) m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-023-01841-8","journal-title":"Mol Cancer"},{"key":"5630_CR58","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/gutjnl-2022-328845","volume":"72","author":"Y Bao","year":"2023","unstructured":"Bao Y, Zhai J, Chen H et al (2023) Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut 72:1497\u20131509","journal-title":"Gut"},{"key":"5630_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2024.1398289","author":"E Zheng","year":"2024","unstructured":"Zheng E, W\u0142odarczyk M, W\u0119giel A et al (2024) Navigating through novelties concerning mCRC treatment\u2014the role of immunotherapy, chemotherapy, and targeted therapy in mCRC. Front Surg. https:\/\/doi.org\/10.3389\/fsurg.2024.1398289","journal-title":"Front Surg"},{"key":"5630_CR60","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1158\/2159-8290.CD-23-1212","volume":"14","author":"S Wang","year":"2024","unstructured":"Wang S, Zeng Y, Zhu L et al (2024) The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma. Cancer Discov 14:2279\u20132299","journal-title":"Cancer Discov"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05630-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05630-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:15:25Z","timestamp":1787908525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05630-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["5630"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05630-x","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}